KIT and gastrointestinal stromal tumor: In Japan, the use of imatinib at doses higher than 400 mg/day is not covered by insurance for GIST, but the efficacy of imatinib 800 mg/day for GIST harboring c-kit exon 9 mutation has been reported [138] and is recommended in global guidelines [46].